Find Reports

Select Report Type

Learn More about Reports

Reimbursement Review

Displaying 1251 - 1258 of 1258

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 576 - 589 of 589

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 111 of 111

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 40 of 40

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 1326 - 1350 of 2093

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
lurasidone		Nov 6, 2019	Reimbursement Review		Not filed	NS0010-000
Healthy Aging		Oct 31, 2019	Health Technology Review			ES0342-000
Screening and Diagnostic Services for People at Risk of Breast Cancer: A Rapid Qualitative Review	Screening and Diagnostic Services for People at Risk of Breast Cancer: A Rapid …	Oct 31, 2019	Health Technology Review	Rapid Review	Completed	RC1208-000
nitisinone	SR0531_Orfadin_complete_Feb-23-18.pdf SR0531_Orfadin_CL_Report.pdf SR0531_Orfadin_PE_Report.pdf SR0531_Orfadin_PI.pdf	Oct 29, 2019	Reimbursement Review		Complete	SR0531-000
doravirine	SR0582 Pifeltro - CDEC Final Recommendation May 16, 2019 for posting.pdf sr0582-pifeltro-clinical-review-report.pdf sr0582-pifeltro-pharmacoeconomic-review-report.pdf sr0582-pifeltro-patient-input.pdf	Oct 29, 2019	Reimbursement Review		Complete	SR0582-000
risankizumab	TS0001-PsO-Updated-Streamlined-Rec.pdf SR0583 Skyrizi - CDEC Final Recommendation May 28, 2019_For posting.pdf sr0583-skyrizi-clinical-review-report.pdf sr0583-skyrizi-pharmacoeconomic-review-report.pdf sr0583-risankizumab-patient-input.pdf	Oct 29, 2019	Reimbursement Review		Complete	SR0583-000
Nelarabine for Acute Lymphoblastic Leukemia - Details	media:document:abc80240-66c6-4de9-a8dd-09954ff23ba5	Oct 29, 2019	Reimbursement Review		Cancelled	PC0170-000
Dementia Villages		Oct 24, 2019	Horizon Scan	Emerging Health Technologies	Completed	EH0071-000
Dementia Villages - Position Statement		Oct 24, 2019	Horizon Scan			EH0071-000
Dementia Villages: Innovative Residential Care for People With Dementia		Oct 24, 2019	Horizon Scan			EH0071-000
telotristat	SR0580_telotristat_PI Submission.pdf SR0580 Xermelo - CDEC Final Recommendation July 3, 2019_For Posting.pdf sr0580-xermelo-clinical-review-report.pdf sr0580-xermelo-pharmacoeconomic-review-report.pdf	Oct 23, 2019	Reimbursement Review		Complete	SR0580-000
dolutegravir / lamivudine	SR0601 Dovato - CDEC Final Recommendation October 2, 2019_for posting.pdf sr0601-dovato-clinical-review-report.pdf sr0601-dovato-pharmacoeconomic-review-report.pdf sr0601-dovato-patient-input.pdf	Oct 23, 2019	Reimbursement Review		Complete	SR0601-000
fluocinolone acetonide intravitreal implant	SR0608 Iluvien - CDEC Final Recommendation September 30, 2019_for posting.pdf sr0608-iIluvien-clinical-review-report.pdf sr0608-iIluvien-pharmacoeconomic-review-report.pdf SR0608-Iluvien-patient-input.pdf	Oct 23, 2019	Reimbursement Review		Complete	SR0608-000
Keytruda Metastatic Urothelial Carcinoma (first line) – Details	PembrolizumabKeytruda_MUCfirstline10177ProvFunding.pdf 10177PembrolizumabMUC(firstline)_FnRec_REDACT_Post_03Oct2019_final.pdf 10177PembrolizumabMUC(firstline)_fnEGR_NOREDACT-ABBREV_Post_03Oct2019_final.pdf 10177PembrolizumabMUC(firstline)_fnCGR_REDACT_Post_03Oct2019_final.pdf 10177PembrolizumabMM(first line)_InRec_REDACT_Post_01Aug2019_final.pdf 10177PembrolizumabMUC(firstline)_PAGFeedbackSummary_FINAL_Post_03Oct2019_final.pdf 10177PembrolizumabMUC(firstline)_SubmitterFeedback_2019-08-16_Post_03Oct2019_final.pdf 10177PembrolizumabMUC(firstline)_PatientFeedback_BCC_2019-08-16__Post_03Oct2019_final.pdf 10177PembrolizumabMUC(firstline)_ClinicianFeedback_CCO_2019-08-16_Post_03Oct2019_final.pdf 10177PembrolizumabMUC(firstline)_PtGrp_COI_Post_03Oct2019_final_Redacted.pdf 10177PembrolizumabMUC(firstline)_Combined ClinicianCOIs_Post_03Oct2019_final.pdf	Oct 21, 2019	Reimbursement Review		Complete	PC0177-000
Health Technology Update — Issue 24		Oct 18, 2019	Horizon Scan	Health Technology Update	Completed	EN0014-000
Hemin for Injection (Panhematin): Budget Impact Analysis	ob0006_porphyria-report-redacted-final.pdf	Oct 16, 2019	Health Technology Review		Completed	OB0006-000
tofacitinib		Oct 9, 2019	Reimbursement Review		Cancelled	SR0575-000
Pomalyst in combination with dexamethasone and bortezomib for Multiple Myeloma (second-line or beyond) – Details	PomalidomidePomalystDex&Bortez_MM2ndline10165_ProvFunding.pdf 10165PomalidomideBortezomibMM_fnRec_EarlyConv_18Sep2019_final.pdf 10165PomalidomideBortezomibMM_fnEGR_NOREDACT-ABBREV_EarlyConv_Post_18Sep2019_final.pdf 10165PomalidomideBortezomibMM_fnCGR_REDACT_EarlyConv_Post_18Sep2019_final.pdf 10165PomalidomideBortezomibMM_InRec_approvedbyChair_Post_29Aug2019_final.pdf 10165PomalidomideBortezomibMM_PAGFeedbackSummary_FINAL_Post_18Sep2019_final.pdf 10165PomalidomideBortezomibMM_SubmitterFeedback_2019-09-13_Post_18Sep2019_final.pdf 10165PomalidomideBortezomibMM_ClinicianFeedback_CCO_2019-09-09_Post_18Sep2019_final.pdf 10165PomalidomideBortezomibMM_COI_Post_18Sep2019_final.pdf 10165PomalidomideBortezomibMM_Combined Clinician_COI_Post_18Sep2019_final.pdf	Oct 3, 2019	Reimbursement Review		Complete	PC0165-000
Second-Line Therapy for Patients with Relapsing-Remitting Multiple Sclerosis: A Review of Guidelines	RC1190 RRMS Second-line therapy Final.pdf	Sep 26, 2019	Health Technology Review	Summary with Critical Appraisal		RC1190-000
Darzalex in combo with Bortezomib, Melphalan and Prednisone for Multiple Myeloma (newly diagnosed) – Details	DaratumumabDarzalex_NewlyDiagnosedMM10148_ProvFunding.pdf 10148Daratumumab+VMPforMM_fnRec_REDACT_Post_29Aug2019_final.pdf 10148Daratumumab+VMPforMM_fnEGR_NOREDACT-ABBREV_Post_29Aug2019_final.pdf 10148Daratumumab+VMPforMM_fnCGR_REDACT_Post_29Aug2910_final.pdf 10148Daratumumab+VMPforMM_inRec_ApprovedbyChair_REDACT_Post_05Jul2019_final.pdf 10148Daratumumab+VMPforMM_PAGFeedbackSummary_FINAL_2019-07-16_Post_29Aug2019_final.pdf 10148Daratumumab+VMPforMM_SubmitterFeedback_2019-07-19_Post_29Aug2019_final.pdf 10148Daratumumab+VMPforMM_PatientFeedback_MC_2019-07-08_Post_29Aug2019_final.pdf 10148Daratumumab+VMPforMM_ClinicianFeedback_CCO_2019-07-15_Post_29Aug2019_final.pdf 10148Daratumumab+VMPforMM_PatientI_COI_Post_29Aug2019.pdf 10148Daratumumab+VMPforMM_Combined Clinician COIs_Post_28Aug2019_Redacted.pdf	Sep 16, 2019	Reimbursement Review		Complete	PC0148-000
Collaboration in Health Technology Assessment in Canada: An Environmental Scan		Sep 13, 2019	Health Technology Review	Environmental Scan	Completed	ES0329-000
baricitinib	SR0597 Olumiant - Patient Group Input_February 7, 2019.pdf sr0597-olumiant-clinical-review-report.pdf sr0597-olumiant-pharmacoeconomic-review-report.pdf SR0597 Olumiant - CDEC Final Recommendation_for posting.pdf	Sep 12, 2019	Reimbursement Review		Complete	SR0597-000
Hemlibra (Emicizumab): Economic Review Report	ob0005-emicizumab-eeconomic-report.pdf	Sep 11, 2019	Health Technology Review		Completed	OB0005-000
patisiran	SR0598_Onpattro-patient-input.pdf SR0598 Onpattro - CDEC Final Recommendation July 29, 2019 for posting.pdf sr0598-onpattro-clinical-review-report.pdf sr0598-onpattro-pharmacoeconomic-review-report.pdf	Sep 6, 2019	Reimbursement Review		Complete	SR0598-000
Latanoprostene bunod	sr0590-vyzulta-clinical-review-report.pdf sr0590-vyzulta-pharmacoeconomic-review-report.pdf sr0590-vyzulta-patient-input.pdf SR0590 Vyzulta - CDEC Final Recommendation July 26, 2019 _for posting.pdf	Sep 6, 2019	Reimbursement Review		Complete	SR0590-000